Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date

Nikoo, Marzieh; Rabiee, Fatemeh; Mohebbi, Hossein; Eghbalifard, Negar; Rajabi, Hamid; Yazdani, Yalda; Sakhaei, Delaram; Khosravifarsani, Mohammadreza; Akhavan-Sigari, Reza

dc.contributor.author	Akhavan-Sigari, Reza
dc.date.accessioned	2023-08-15T09:33:59Z
dc.date.available	2023-08-15T09:33:59Z
dc.date.issued	2023
dc.identifier.issn	1567-5769
dc.identifier.uri	http://hdl.handle.net/10900/144272
dc.language.iso	en	de_DE
dc.publisher	Elsevier	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/j.intimp.2023.109881	de_DE
dc.subject.ddc	570	de_DE
dc.subject.ddc	610	de_DE
dc.title	Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date	de_DE
dc.type	Article	de_DE
utue.quellen.id	20230619000000_00889
utue.personen.roh	Nikoo, Marzieh
utue.personen.roh	Rabiee, Fatemeh
utue.personen.roh	Mohebbi, Hossein
utue.personen.roh	Eghbalifard, Negar
utue.personen.roh	Rajabi, Hamid
utue.personen.roh	Yazdani, Yalda
utue.personen.roh	Sakhaei, Delaram
utue.personen.roh	Khosravifarsani, Mohammadreza
utue.personen.roh	Akhavan-Sigari, Reza
dcterms.isPartOf.ZSTitelID	International Immunopharmacology	de_DE
dcterms.isPartOf.ZS-Issue	Article 109881	de_DE
dcterms.isPartOf.ZS-Volume	117	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE